Feature

Does the Role of CDMO Need to Evolve?

In short: Yes, says Mat Minardi, Chief Scientific Officer at Sterling Pharma Solutions

Share

Contract Development and Manufacturing Organizations (CDMOs) are pivotal in aiding pharmaceutical innovation, especially as geopolitical dynamics and complex drug molecules challenge traditional operational models. Mat Minardi from Sterling Pharma Solutions emphasizes the need for CDMOs to rethink their talent deployment and establish strategic long-term partnerships with big pharma. As drug development accelerates, organizations must adapt to provide efficient, cost-effective solutions while navigating pressures on funding and market readiness, ensuring patient-centric outcomes remain paramount.

Related Content

Vaccine Guidance Splits: Now What?

Liability remains low, coverage stable as clinicians navigate fractured federal guidance

Is Point-of-Care Hepatitis C Virus Testing Too Expensive?

RNA testing carries substantial cost burden for hospitals, study finds

  • January 14, 2026

  • 2 min
Medical Oddities: A Vaccine With a Foam Head?

A week of bold ideas: drinkable vaccines, unrealistic TV CPR, yoga-assisted detox, and meat-heavy math.